🏗️ Building the Future of Nuclear Medicine LBT Phase II Project As nuclear medicine advances toward theranostics, emerging medical isotopes, BNCT, and advanced accelerator technologies, LBT is invest

2026-06-29

As nuclear medicine advances toward theranostics, emerging medical isotopes, BNCT, and advanced accelerator technologies, LBT is investing in the next stage of its development with the Phase II Project.

🚧 Construction Update

The project is progressing steadily and is expected to be completed by the end of 2026.

With a total investment of RMB 150 million and a construction area of approximately 8,339 m², the new facility is currently in the main structural construction phase and will provide dedicated production, assembly, testing, and R&D space.

⚛️ Future Capabilities

Phase II will significantly expand LBT’s capabilities in:

• Medical isotope production using 20–30 MeV cyclotrons and a petal electron accelerator, supporting isotopes including ⁴⁴Sc, ⁶⁴Cu, ⁶⁷Cu, ⁸⁹Zr, ¹²⁴I, ²¹¹At, ²²⁵Ac, and ⁶⁸Ge.

• Medium-energy cyclotron manufacturing, with an annual capacity of 20 cyclotrons, including 8+ units of the 30 MeV platform.

• BNCT technology development, with a planned production capacity of at least four BNCT systems per year.

🌍 Looking Ahead

More than an expansion project, Phase II represents LBT’s long-term commitment to advancing accelerator technologies, medical isotope production, and next-generation nuclear medicine solutions.

Stay tuned as we continue sharing the journey of Phase II.

#NuclearMedicine #Cyclotron #MedicalCyclotron #Radioisotopes #Radiopharmacy #BNCT #Theranostics #MedicalIsotopes #LongevousBeamtech